BRD2 and myeloid sarcoma: Second, it reframes integrin signaling in MS: while α4 integrins have long been established as central to lymphocyte trafficking across the BBB [23] and serve as therapeutic targets for NAT, our findings suggest that ITGB3 could represent an alternative or complementary immune checkpoint integrin modulating peripheral immune activity, BBB dynamics, and disease progression.